ZA201706605B - Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) - Google Patents

Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Info

Publication number
ZA201706605B
ZA201706605B ZA2017/06605A ZA201706605A ZA201706605B ZA 201706605 B ZA201706605 B ZA 201706605B ZA 2017/06605 A ZA2017/06605 A ZA 2017/06605A ZA 201706605 A ZA201706605 A ZA 201706605A ZA 201706605 B ZA201706605 B ZA 201706605B
Authority
ZA
South Africa
Prior art keywords
gpc3
glypican
muteins
affinity
human lipocalin
Prior art date
Application number
ZA2017/06605A
Other languages
English (en)
Inventor
Marlon Hinner
Andrea Allersdorfer
Aiba Rachida Siham Bel
Michaela Aloe
Alexander Wiedenmann
Gabriele Matschiner
Martin Huelsmeyer
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of ZA201706605B publication Critical patent/ZA201706605B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
ZA2017/06605A 2015-05-18 2017-10-02 Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) ZA201706605B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15167922 2015-05-18
PCT/EP2016/061058 WO2016184875A1 (en) 2015-05-18 2016-05-18 Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Publications (1)

Publication Number Publication Date
ZA201706605B true ZA201706605B (en) 2020-05-27

Family

ID=53180583

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/06605A ZA201706605B (en) 2015-05-18 2017-10-02 Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Country Status (13)

Country Link
US (2) US10273275B2 (enExample)
EP (1) EP3298029A1 (enExample)
JP (2) JP6942060B2 (enExample)
KR (1) KR20180008649A (enExample)
CN (2) CN107787327B (enExample)
AU (1) AU2016262838B2 (enExample)
BR (1) BR112017020961A2 (enExample)
CA (1) CA2982034A1 (enExample)
MX (1) MX2017014730A (enExample)
RU (1) RU2756318C2 (enExample)
SG (1) SG11201707872WA (enExample)
WO (1) WO2016184875A1 (enExample)
ZA (1) ZA201706605B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201408073XA (en) 2009-12-07 2015-01-29 Pieris Ag Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
EP3441400B1 (en) 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
ES2823563T3 (es) 2014-05-22 2021-05-07 Pieris Pharmaceuticals Gmbh Polipéptidos de unión específica novedosos y usos de los mismos
KR20170105609A (ko) 2015-01-28 2017-09-19 피어이스 파마슈티컬즈 게엠베하 신생혈관형성에 특이적인 신규한 단백질
EP4378962A3 (en) 2015-05-04 2024-07-31 Pieris Pharmaceuticals GmbH Anti-cancer fusion polypeptide
DK3292137T3 (da) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
WO2016184875A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
SG11201803732PA (en) 2015-11-30 2018-06-28 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
MX2021010039A (es) 2019-02-26 2021-09-21 Pieris Pharmaceuticals Gmbh Novedosas proteinas de fusion especificas para cd137 y gpc3.
WO2020201038A1 (en) 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
CN116249709A (zh) 2020-06-05 2023-06-09 皮里斯制药有限公司 靶向4-1bb的多聚体免疫调节剂

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
EP0759939B1 (en) 1994-05-18 2005-07-20 Nektar Therapeutics Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
EP1087778B1 (en) 1998-06-08 2005-10-26 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7235520B2 (en) 2000-09-21 2007-06-26 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
WO2002076489A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
PT1923463E (pt) * 2005-08-09 2011-11-24 Oncotherapy Science Inc Péptido antigénico de rejeição do cancro derivado de glipicano 3 (gpc3) para ser utilizado em doentes positivos para hla-a2 e composições farmacêuticas que contêm o antigénio
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8598317B2 (en) * 2006-03-20 2013-12-03 Technische Universitaet Muenchen Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
DE602007009995D1 (de) 2006-08-01 2010-12-02 Pieris Ag Muteine von tearlipocalin und verfahren zu deren gewinnung
PL2178921T3 (pl) 2007-07-17 2016-06-30 Squibb & Sons Llc Monoklonalne przeciwciała przeciwko glipikanowi-3
WO2009052390A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
SG10201408073XA (en) 2009-12-07 2015-01-29 Pieris Ag Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
EP2576587B1 (en) 2010-05-24 2018-03-21 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
WO2011154420A2 (en) 2010-06-08 2011-12-15 Pieris Ag Tear lipocalin muteins binding il-4 r alpha
DK2606061T3 (da) 2010-08-16 2017-11-06 Pieris Pharmaceuticals Gmbh Bindingsproteiner til hepcidin
DK2640740T3 (en) * 2010-11-15 2017-06-26 Pieris Pharmaceuticals Gmbh MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
US20130225505A1 (en) 2011-11-23 2013-08-29 Allergan, Inc. Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
EP3441400B1 (en) * 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
KR20170105609A (ko) 2015-01-28 2017-09-19 피어이스 파마슈티컬즈 게엠베하 신생혈관형성에 특이적인 신규한 단백질
KR20170116158A (ko) 2015-02-18 2017-10-18 사노피 피오베르딘 및 피오켈린에 특이적인 신규한 단백질
DK3292137T3 (da) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
WO2016184875A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Also Published As

Publication number Publication date
CN107787327A (zh) 2018-03-09
US10787491B2 (en) 2020-09-29
US20180141988A1 (en) 2018-05-24
US20190309037A1 (en) 2019-10-10
CN107787327B (zh) 2022-02-08
RU2017135605A (ru) 2019-06-18
RU2017135605A3 (enExample) 2019-11-13
BR112017020961A2 (pt) 2018-07-10
JP2018519802A (ja) 2018-07-26
WO2016184875A1 (en) 2016-11-24
US10273275B2 (en) 2019-04-30
JP6942060B2 (ja) 2021-09-29
EP3298029A1 (en) 2018-03-28
KR20180008649A (ko) 2018-01-24
RU2756318C2 (ru) 2021-09-29
JP2021184725A (ja) 2021-12-09
CA2982034A1 (en) 2016-11-24
AU2016262838A1 (en) 2018-01-04
SG11201707872WA (en) 2017-10-30
MX2017014730A (es) 2018-06-28
JP7217783B2 (ja) 2023-02-03
AU2016262838B2 (en) 2020-10-08
CN114456252A (zh) 2022-05-10

Similar Documents

Publication Publication Date Title
ZA201706605B (en) Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
IL292094A (en) Neoantigens and methods for using them
IL275468A (en) Incretin analogs and their use
IL286316A (en) New micro-dystrophins and related method of use
IL274151A (en) Trispecific binding proteins and methods of use
IL275469A (en) Incretin analogs and their use
IL261432A (en) Induced binding proteins and methods of use
IL259660B (en) Apelin receptor agonists and methods of use
PT3235830T (pt) Complexo proteico de interleucina 15 e sua utilização
ZA201802542B (en) New polypeptide having affinity to pd-l1
IL254089A0 (en) Desacetoxytobulizin h and its analogs
EP3268477A4 (en) Structure based methods for modification of pip-72 polypeptides and pip-72 polypeptides derived therefrom
GB2546617B (en) Apparatus and methods for determining electrical conductivity of tissue
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
SG10202102733RA (en) Breath sampling interface
IL261906A (en) Biomarkers for proteopathies and their uses
EP3161490A4 (en) COMPOSITIONS AND METHODS FOR DETECTING HUMAN PEGIVIRUS 2 (HPgV-2)
GB201522184D0 (en) Measurement and control of lighting
HUP1500436A2 (hu) Sokcsatornás fizikoterápiás berendezés és eljárás annak alkalmazására
SG11201710519PA (en) Evaluation of inhibitory circuit and use thereof
SMT202200380T1 (it) Composizione di rmp e metodi d'uso
IL242133B (en) Back-carryable shooting kit and method of use thereof